Chennai: Hyderabad-based, Avra Laboratories Pvt Ltd has been granted regulatory approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Favipiravir API, which will help patients suffering from Covid-19.
Avra Laboratories, according to a statement, has developed an alternative low cost and highly efficient manufacturing process and is now supplying commercial quantities to Cipla for the launch of Ciplenza, the generic version of Favipiravir.
Dr A V Rama Rao, chairman, Avra Laboratories said, “I am very pleased to be working with Cipla and Dr Yusuf Hamied again with whom I share a five-decade long association and friendship, during which time we collaborated on several projects to produce lifesaving drugs including anti-cancer, anti-HIV/AIDS and several other generic products. The current pandemic has brought us together to work tirelessly for the speedy launch of Favipiravir”.